| scholarly article | Q13442814 |
| P2093 | author name string | Kan Kikuchi | |
| Guy Amit | |||
| Victor Novack | |||
| Ian D Greener | |||
| J Kevin Donahue | |||
| Lizhu Yang | |||
| P2860 | cites work | Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort | Q77960625 |
| Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat | Q80233954 | ||
| Minimally invasive surgical ablation of atrial fibrillation: six-month results | Q84169933 | ||
| An 8 1/2-year clinical experience with surgery for atrial fibrillation | Q24535788 | ||
| Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature | Q28379324 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| A multicenter risk index for atrial fibrillation after cardiac surgery | Q34547092 | ||
| Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? | Q34683038 | ||
| Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress | Q35214033 | ||
| Molecular ablation of ventricular tachycardia after myocardial infarction | Q35613114 | ||
| Port-access coronary artery bypass grafting: a proposed surgical method. | Q36795869 | ||
| Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology | Q36841676 | ||
| Safety considerations in the pharmacological management of atrial fibrillation | Q37055677 | ||
| A pilot study to estimate the feasibility of assessing the relationships between polymorphisms in hKv1.5 and atrial fibrillation in patients following coronary artery bypass graft surgery | Q37073576 | ||
| Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF | Q37153406 | ||
| Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector | Q37251114 | ||
| Prevalence of early-onset atrial fibrillation in congenital long QT syndrome | Q37613105 | ||
| Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer | Q38475677 | ||
| Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication-defective adenovirus | Q39430823 | ||
| Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence | Q40310174 | ||
| Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy | Q43678581 | ||
| Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors | Q43716886 | ||
| Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study | Q43984938 | ||
| Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation | Q45124648 | ||
| Focal modification of electrical conduction in the heart by viral gene transfer | Q45872810 | ||
| Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. | Q45999295 | ||
| Atrial fibrillation after isolated coronary surgery affects late survival | Q46340475 | ||
| Competing autonomic mechanisms precedethe onset of postoperative atrial fibrillation | Q47591217 | ||
| Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. | Q51025232 | ||
| Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. | Q53872064 | ||
| Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality | Q57073207 | ||
| The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG) | Q57251838 | ||
| Prolonged Atrial Action Potential Durations and Polymorphic Atrial Tachyarrhythmias in Patients with Long QT Syndrome | Q57628082 | ||
| The emerging role of inflammation in atrial fibrillation and the potential of anti-inflammatory interventions | Q57806783 | ||
| A New Technique to Perform Epicardial Mapping in the Electrophysiology Laboratory | Q58757821 | ||
| Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure | Q76383244 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Atrial Fibrillation | Q815819 |
| P304 | page(s) | 2263-2270 | |
| P577 | publication date | 2010-05-17 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Selective molecular potassium channel blockade prevents atrial fibrillation | |
| P478 | volume | 121 |
| Q46504188 | Ablatogenomics: can genotype guide catheter ablation for cardiac arrhythmias? |
| Q38413814 | Atrial overexpression of angiotensin-converting enzyme 2 improves the canine rapid atrial pacing-induced structural and electrical remodeling. Fan, ACE2 improves atrial substrate remodeling |
| Q33561535 | Attraction of rotors to the pulmonary veins in paroxysmal atrial fibrillation: a modeling study. |
| Q36934761 | Biological Therapies for Atrial Fibrillation: Ready for Prime Time? |
| Q47286154 | Biological therapies targeting arrhythmias: are cells and genes the answer? |
| Q42845231 | Blockade of permeation by potassium but normal gating of the G628S nonconducting hERG channel mutant |
| Q37981008 | Cardiac gene therapy in large animals: bridge from bench to bedside. |
| Q27014770 | Cardiovascular gene therapy for myocardial infarction |
| Q45872188 | Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model |
| Q38790389 | Connexin Remodeling Contributes to Atrial Fibrillation |
| Q38435600 | Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. |
| Q39741408 | Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. |
| Q39392472 | Current state of the art for cardiac arrhythmia gene therapy |
| Q36189106 | Effect of skeletal muscle Na(+) channel delivered via a cell platform on cardiac conduction and arrhythmia induction |
| Q45866944 | Emerging molecular therapies targeting myocardial infarction-related arrhythmias |
| Q35001371 | Expression changes of ionic channels in early phase of cultured rat atrial myocytes induced by rapid pacing |
| Q39332399 | Gene Therapy for Atrial Fibrillation in Heart Failure. |
| Q39815208 | Gene Therapy for Cardiac Arrhythmias |
| Q38132253 | Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium |
| Q37778878 | Gene therapy strategies for cardiac electrical dysfunction |
| Q38416938 | Gene therapy to restore electrophysiological function in heart failure |
| Q38444909 | Gene therapy to treat cardiac arrhythmias |
| Q37310450 | Gene therapy to treat cardiovascular disease |
| Q57823807 | Human Cardiac Gene Therapy |
| Q38828102 | Improving Atrial Fibrillation Therapy: Is There a Gene for That? |
| Q37989142 | Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteins |
| Q36939738 | Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation |
| Q58617305 | Oxidative stress creates a unique, CaMKII-mediated substrate for atrial fibrillation in heart failure |
| Q38400203 | Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation. |
| Q35142870 | Recent advances in the molecular pathophysiology of atrial fibrillation. |
| Q37821376 | Regenerative therapies in electrophysiology and pacing: introducing the next steps |
| Q47093808 | SVT Therapy - Yesterday, Today and Tomorrow? |
| Q36135223 | SkM1 and Cx32 improve conduction in canine myocardial infarcts yet only SkM1 is antiarrhythmic |
| Q50488818 | Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers. |
| Q45872055 | Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study |
| Q36604734 | Targeted nonviral gene-based inhibition of Gα(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. |
| Q37523818 | The Major Role of IK1 in Mechanisms of Rotor Drift in the Atria: A Computational Study |
| Q91707072 | The Reversal Effect of Sigma-1 Receptor (S1R) Agonist, SA4503, on Atrial Fibrillation After Depression and Its Underlying Mechanism |
| Q36458906 | The Use of Gene Therapy for Ablation of Atrial Fibrillation |
| Q34772923 | The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation |
Search more.